Orelabrutinib-Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Study

被引：0
|
作者：
Li, He [1 ]
Liu, Jiazhuo [1 ]
Chen, Yuhui [1 ]
Tuohuti, Pazilaiti [1 ]
Wang, Yutong [1 ]
Tang, Xinzhu [1 ]
Xiang, Bing [1 ]
Jia, Yongqian [1 ]
Wu, Yu [1 ]
Tang, Yun [1 ]
Guo, Yong [1 ]
Wang, Jie [1 ]
Zheng, Yuhuan [1 ]
Liu, Yu [1 ]
Niu, Ting [1 ,2 ,3 ]
机构：
[1] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Natl Facil Translat Med Sichuan, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, State Key Lab Biotherapy, Chengdu, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-206464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6308 / 6309
页数：2
相关论文
共 50 条
  • [1] Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study
    Jing-Jing Wu
    Wen-Hua Wang
    Meng Dong
    Shan-Shan Ma
    Xu-Dong Zhang
    Li-Nan Zhu
    Song-Tao Niu
    Meng-Jie Ding
    Jie-Ming Zhang
    Lei Zhang
    Xin Li
    Ling Li
    Zhen-Chang Sun
    Xin-Hua Wang
    Xiao-Rui Fu
    Zhao-Ming Li
    Yu Chang
    Fei-Fei Nan
    Jia-Qin Yan
    Hui Yu
    Xiao-Long Wu
    Zhi-Yuan Zhou
    Ming-Zhi Zhang
    Investigational New Drugs, 2022, 40 : 650 - 659
  • [2] Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study
    Wu, Jing-Jing
    Wang, Wen-Hua
    Dong, Meng
    Ma, Shan-Shan
    Zhang, Xu-Dong
    Zhu, Li-Nan
    Niu, Song-Tao
    Ding, Meng-Jie
    Zhang, Jie-Ming
    Zhang, Lei
    Li, Xin
    Li, Ling
    Sun, Zhen-Chang
    Wang, Xin-Hua
    Fu, Xiao-Rui
    Li, Zhao-Ming
    Chang, Yu
    Nan, Fei-Fei
    Yan, Jia-Qin
    Yu, Hui
    Wu, Xiao-Long
    Zhou, Zhi-Yuan
    Zhang, Ming-Zhi
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (03) : 650 - 659
  • [3] Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
    Noy, Ariela
    de Vos, Sven
    Thieblemont, Catherine
    Martin, Peter
    Flowers, Christopher R.
    Morschhauser, Franck
    Collins, Graham P.
    Ma, Shuo
    Coleman, Morton
    Peles, Shachar
    Smith, Stephen
    Barrientos, Jacqueline C.
    Smith, Alina
    Munneke, Brian
    Dimery, Isaiah
    Beaupre, Darrin M.
    Chen, Robert
    BLOOD, 2017, 129 (16) : 2224 - 2232
  • [4] Orelabrutinib, a Selective Bruton's Tyrosine Kinase (BTK) Inhibitor in the Treatment of Primary Immune Thrombocytopenia (ITP)
    Yu, Tianshu
    Wang, Lingjun
    Ni, Xiaofei
    Hou, Yu
    Liu, Xinguang
    Hou, Ming
    BLOOD, 2021, 138
  • [5] The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
    Opat, Stephen
    Tedeschi, Alessandra
    Linton, Kim
    McKay, Pamela
    Hu, Bei
    Chan, Henry
    Jin, Jie
    Sobieraj-Teague, Magdalena
    Zinzani, Pier Luigi
    Coleman, Morton
    Thieblemont, Catherine
    Browett, Peter
    Ke, Xiaoyan
    Sun, Mingyuan
    Marcus, Robert
    Portell, Craig A.
    Ardeshna, Kirit
    Bijou, Fontanet
    Walker, Patricia
    Hawkes, Eliza A.
    Mapp, Sally
    Ho, Shir-Jing
    Talaulikar, Dipti
    Zhou, Ke-Shu
    Co, Melannie
    Li, Xiaotong
    Zhou, Wenxiao
    Cappellini, Massimo
    Tankersley, Chris
    Huang, Jane
    Trotman, Judith
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6323 - 6332
  • [6] TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis
    Cherng, Hua-Jay J.
    Khwaja, Raamis
    Kanagal-Shamanna, Rashmi
    Tang, Guilin
    Burger, Jan
    Thompson, Philip
    Ferrajoli, Alessandra
    Estrov, Zeev
    Sasaki, Koji
    Sampath, Deepa
    Wang, Xuemei
    Kantarjian, Hagop
    Keating, Michael
    Wierda, William G.
    Jain, Nitin
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (08) : 1005 - 1012
  • [7] Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study
    Deng, Lijuan
    Li, Zhiming
    Zhang, Huilai
    Huang, Haiwen
    Hu, Jianda
    Liu, Lihong
    Liu, Ting
    Jin, Jie
    Zhu, Zunmin
    Li, Wenyu
    Huang, Zhenqian
    Huang, Wenrong
    Zhou, Keshu
    Yang, Haiyan
    Zhang, Mingzhi
    Ding, Kaiyang
    Zhou, Hui
    Hu, Yu
    Shuang, Yuerong
    Cao, Junning
    Gao, Sujun
    Li, Dengju
    Sun, Zimin
    Zhang, Qingyuan
    Yi, Shuhua
    Ji, Chunyan
    Zhang, Liansheng
    Hou, Cheng
    Du, Yue
    Wang, Weige
    Zhao, Renbin
    Song, Yuqin
    Zhu, Jun
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1742 - 1750
  • [8] Preliminary Results of a Retrospective Study on a Regimen Based on Orelabrutinib Combined with Anti-CD20 Monoclonal Antibody in Patients with Marginal Zone Lymphoma
    Peng, Hongling
    Xiang, Xixi
    Rao, Jun
    Yan, Wenzhe
    Cui, Yajuan
    Li, Ji
    Jiang, Yafeng
    Zhang, Xi
    BLOOD, 2024, 144 : 6293 - 6293
  • [9] Atypical lymphocytic lymphoma transitioning into dendritic cell sarcoma after bruton's tyrosine kinase inhibitor treatment
    Zuniga Gaitan, J. T.
    Bosch Schips, M.
    Montana Ramirez, A. M.
    Castellvi Vives, J.
    VIRCHOWS ARCHIV, 2024, 485 : S324 - S324
  • [10] A pilot study of the efficacy of a bruton's tyrosine kinase inhibitor in the treatment of dogs with pemphigus foliaceus
    Murrell, D.
    Gourlay, S. M.
    Hill, R. J.
    Bisconte, A.
    Francesco, M.
    Smith, P.
    Karr, D.
    Outerbridge, C.
    Varjonen, K.
    Goodale, E. C.
    Borjesson, D.
    Werth, V. P.
    Nuun, P. A.
    White, S. D.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 73 - 73
12345